Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBITDA Margin (2019 - 2023)

Benitec Biopharma's EBITDA Margin history spans 5 years, with the latest figure at 66257.14% for Q2 2023.

  • For Q2 2023, EBITDA Margin changed N/A year-over-year to 66257.14%; the TTM value through Mar 2024 reached 309628.57%, down 28122416.0%, while the annual FY2023 figure was 25529.33%, 87454.0% down from the prior year.
  • EBITDA Margin for Q2 2023 was 66257.14% at Benitec Biopharma, down from 8059.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 5256.1% in Q2 2020 and bottomed at 393300.0% in Q1 2021.
  • The 5-year median for EBITDA Margin is 10725.0% (2020), against an average of 80672.43%.
  • The largest annual shift saw EBITDA Margin tumbled -38257500bps in 2021 before it skyrocketed 38599167bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 2277.92% in 2019, then tumbled by -13263bps to 304400.0% in 2020, then soared by 94bps to 19512.0% in 2021, then crashed by -104bps to 39792.86% in 2022, then tumbled by -67bps to 66257.14% in 2023.
  • Per Business Quant, the three most recent readings for BNTC's EBITDA Margin are 66257.14% (Q2 2023), 8059.26% (Q1 2023), and 39792.86% (Q4 2022).